FDA device records linked by MedtechLedger identify Boston Scientific Corporation as the applicant on seven filings retrieved as of November 20, 2026: six premarket approval (PMA) records and one 510(k) record. Across that collection, decisions comprise three OK30, one SESE and three APPR entries. The smaller record sample of five rows shows three OK30, one SESE and one APPR. These counts describe the retrieved filings only and are not measures of total portfolio, sales or safety performance. [1][2][3][4][5]
Radiology and interventional oncology filings
TheraSphere Y-90 Glass Microspheres System appears under PMA P200029. Supplement S015, a 30-Day Notice received September 15, 2026 and decided October 13, 2026 with decision code OK30, covers reinstatement of a previously approved manufacturing room at BWXT Medical Limited for routine manufacture of the Yttrium-90 glass microspheres. The FDA record classifies the generic device as microspheres radionuclide under product code NAW, device class 3, with a radiology advisory committee. [1]
SpaceOAR Flex System was cleared under 510(k) K262151, a traditional clearance with decision code SESE and decision description substantially equivalent, received June 25, 2026 and decided September 11, 2026. The FDA record lists the device as hydrogel spacer, device class 2, regulation number 892.5725, product code OVB, with a radiology advisory committee. [3]
Cardiovascular and neuromodulation supplements
EMBLEM Subcutaneous Implantable Cardioverter Defibrillator high voltage capacitor is covered by PMA P110042 supplement S216, a 30-Day Notice received September 10, 2026 and decided October 2, 2026 with decision code OK30. The order statement describes adjusting manufacturing steps and modifying laser equipment software for the HV capacitors in EMBLEM S-ICD devices. The FDA record lists the generic device as implantable cardioverter defibrillator (non-CRT), product code LWS, device class 3, cardiovascular advisory committee. [2]
eCoin Peripheral Neurostimulator appears twice in the records. The original PMA P200036 was approved March 1, 2022 with decision code APPR; its order statement describes the device as intended to treat urgency urinary incontinence in patients intolerant to or having an inadequate response to more conservative treatments or who have undergone a successful trial of percutaneous tibial nerve stimulation. Supplement S012, a 30-Day Notice received August 13, 2026 and decided September 9, 2026 with decision code OK30, covers a change in the frequency of setting the bioburden recovery efficiency. The FDA record lists product code QPT, device class 3, gastroenterology and urology advisory committee. [4][5]
Manufacturer documentation and record scope
Boston Scientific's published TheraSphere pages describe the product within its interventional radiology and interventional oncology materials and carry corporate copyright notices for 2026. Those pages identify Boston Scientific Medical Device Limited as a wholly owned indirect subsidiary of Boston Scientific Corporation in the context of the product documentation. The pages reviewed do not provide the filing details above; those come from the FDA records. [6][9][10]
The retrieved collection also includes enforcement records naming Boston Scientific products, such as the StoneSmart Connect Console and LUX-Dx insertable cardiac monitor software, alongside catheter and stent listings. Those recall entries are separate from the premarket decision counts and are not evidence of filing outcomes. The decision tallies reported here apply only to the seven retrieved premarket records and the five-row sample. [1][2][3][4][5]










